Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$92.63

-3.29 (-3.43%)

, AVXS

AveXis

$45.16

0.61 (1.37%)

08:07
10/07/16
10/07
08:07
10/07/16
08:07

Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman

Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

BMRN

BioMarin

$92.63

-3.29 (-3.43%)

AVXS

AveXis

$45.16

0.61 (1.37%)

BLUE

bluebird bio

$70.00

-3.12 (-4.27%)

INCY

Incyte

$94.78

-0.91 (-0.95%)

ACOR

Acorda Therapeutics

$20.71

0.04 (0.19%)

FOLD

Amicus

SGEN

Seattle Genetics

$54.33

-1.18 (-2.13%)

GWPH

GW Pharmaceuticals

$133.10

-0.35 (-0.26%)

ONCE

Spark Therapeutics

$60.49

-2.48 (-3.94%)

RDUS

Radius Health

$52.08

-0.93 (-1.75%)

SAGE

SAGE Therapeutics

$43.54

-2.36 (-5.14%)

KITE

Kite Pharma

$55.66

-0.75 (-1.33%)

  • 07

    Oct

  • 07

    Oct

  • 07

    Oct

  • 10

    Oct

  • 12

    Oct

  • 13

    Oct

  • 18

    Oct

  • 06

    Nov

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$92.63

-3.29 (-3.43%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/19/16
RAJA
09/19/16
NO CHANGE
RAJA
Outperform
Sarepta approval opens up revenue stream for BioMarin, says Raymond James
Raymond James analyst Christopher Raymond noted that the FDA approval of Sarepta's (SRPT) eteplirsen for the treatment of exon 51 skipping amenable Duchenne's muscular dystrophy opens up an "unexpected potential revenue stream" for BioMarin (BMRN), which he said currently holds a "dominant patent position" on Exon 51 skipping therapies. The analyst, who thinks BioMarin may stand to benefit from Sarepta's news, keeps an Outperform rating on BioMarin shares.
09/07/16
JPMS
09/07/16
NO CHANGE
JPMS
Overweight
JPMorgan still expects approval of BioMarin's Brineura
JPMorgan analyst Cory Kasimov says he continues to expect BioMarin's Brineura to be approved and launched in the first half of 2017 after the FDA delayed the PDUFA by three months. The key takeaway from last night's announcement, the analyst contends, is that the data with an additional eight month of follow-up is "even stronger." Kasimov is "somewhat surprised" by the extended action date as the drug was also granted priority review and Breakthrough designation. He reiterates an Overweight rating on BioMarin Pharmaceuticals.
AVXS AveXis
$45.16

0.61 (1.37%)

10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
BLUE bluebird bio
$70.00

-3.12 (-4.27%)

09/22/16
ROTH
09/22/16
INITIATION
Target $87
ROTH
Buy
bluebird bio reinstated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach assumed coverage of bluebird bio with a Buy rating and $87 price target based on a sum-of-parts, probability-adjusted NPV analysis of the company's pipeline. The analyst believes bluebird bio can no longer be considered a fledgling given the clinical success seen in its Lenti-D and Lentiglobin programs, both hatched from the company's versatile core lentiviral technology platform.
09/15/16
GSCO
09/15/16
UPGRADE
Target $135
GSCO
Conviction Buy
bluebird bio upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Salveen Richter added bluebird to the Conviction Buy List ahead of numerous catalysts and a value inflection point. Richter expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. The analyst has a $135 price target on bluebird shares.
09/15/16
09/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Hold from Sell at Canaccord with analyst Alex Brooks citing valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from Perform at Oppenheimer analyst Brian Nagel citing the potential for better near-term sales trends as "weaker players" in sporting goods retail fail. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying volume trends across the company's commercial portfolio suggests the base business is "on sustainable footing." 4. Petrobras (PBR) upgraded to Neutral from Underperform at Macquarie with analyst Giacomo Romeo saying near-term liquidity is less concerning after recent divestitures, an improved political outlook, and the re-gained access to the bond market. 5. bluebird bio (BLUE) upgraded to Conviction Buy from Buy at Goldman with analyst Salveen Richter saying he expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
09/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Packaging Corp. (PKG) initiated with a Sell at Goldman. 2. Netlist (NLST) initiated with a Buy at B. Riley. 3. Weyerhaeuser (WY) initiated with a Conviction Buy at Goldman. 4. bluebird bio (BLUE) reinstated with a Buy at Roth Capital. 5. Dentsply Sirona (XRAY) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
INCY Incyte
$94.78

-0.91 (-0.95%)

09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
ACOR Acorda Therapeutics
$20.71

0.04 (0.19%)

03/30/16
GSCO
03/30/16
DOWNGRADE
Target $10
GSCO
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
03/30/16
03/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Intercept (ICPT) initiated with an Outperform and a Neutral at Credit Suisse and Goldman, respectively. Goldman Sachs analyst Salveen Richter said investor expectations into the April 7 FDA panel for obeticholic acid in primary biliary cholangitis appear high. 2. Acorda Therapeutics (ACOR) initiated with a Sell at Goldman by analyst Salveen Richter, who said Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares. 3. SAGE Therapeutics (SAGE) initiated with a Buy at Goldman due to the belief that the company is a key player in acute central nervous system disorders. 4. Rio Tinto (RIO) initiated with a Buy at Argus. 5. Square (SQ) initiated with a Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/30/16
GSCO
03/30/16
INITIATION
Target $23
GSCO
Sell
Acorda Therapeutics initiated with a Sell at Goldman
Goldman Sachs analyst Salveen Richter started Acorda Therapeutics with a Sell rating and $23 price target. The analyst believes Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares.
10/04/16
LEER
10/04/16
INITIATION
Target $25
LEER
Market Perform
Acorda Therapeutics reinstated with a Market Perform at Leerink
Leerink analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Market Perform rating and $25 price target.
FOLD Amicus

05/18/16
BOFA
05/18/16
INITIATION
Target $10
BOFA
Buy
Amicus initiated with a Buy at BofA/Merrill
Target $10.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
06/14/16
LEER
06/14/16
NO CHANGE
Target $19
LEER
Outperform
Protalix development encouraging for Amicus Galafold, says Leerink
Leerink analyst Joseph Schwartz is "incrementally encouraged" by the news that Protalix (PLX) reached an agreement with the FDA to advance its Fabry ERT into a pivotal trial, just before Amicus' (FOLD) meeting with the agency to discuss a regulatory path for its Galafold. Amicus was poised to emphasize non-renal data in the upcoming FDA meeting, but now the company has "another way to win" by using renal data, the analyst tells investors in a research note. Schwartz now assigns a 33% probability for Galafold. The analyst reiterates an Outperform rating on Amicus' stock and raised his price target on the shares to $19 from $17.
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
SGEN Seattle Genetics
$54.33

-1.18 (-2.13%)

09/07/16
MSCO
09/07/16
INITIATION
Target $60
MSCO
Overweight
Seattle Genetics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Andrew Berens initiated Seattle Genetics with an Overweight and $60 price target. The analyst expects Adcetris will peak at $2.5B by 2030 and thinks the company is likely to move Adcetris to the frontline in Hodgkin's lymphoma treatment.
09/16/16
LEER
09/16/16
NO CHANGE
Target $62
LEER
Outperform
Seattle Genetics price target raised to $62 from $52 at Leerink
After assuming coverage of Seattle Genetics, Leerink analyst Michael Schmidt raised the price target on the stock to $62 from $52, saying he sees additional upside for the shares over the next 12-18 months. The analyst has an Outperform rating on Seattle Genetics' stock.
09/15/16
GSCO
09/15/16
UPGRADE
GSCO
Neutral
Seattle Genetics upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst Salveen Richter upgraded Seattle Genetics to Neutral after raising her estimates for Adcetris in Hodgkin lymphoma. The analyst also introduced a takeover component to her valuation given the company's "scarcity of commercial oncology assets and emerging optionality from the pipeline." She raised her price target for Seattle Genetics to $47 from $30. The biotechnology company closed yesterday up $2.36 to $54.06.
GWPH GW Pharmaceuticals
$133.10

-0.35 (-0.26%)

10/07/16
GSCO
10/07/16
INITIATION
Target $189
GSCO
Buy
GW Pharmaceuticals initiated with a Buy at Goldman
Goldman analyst Salveen Richter initiated GW Pharmaceuticals with a Buy saying he expects a solid launch trajectory for lead assets Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome, two severe orphan epilepsies, and is modeling $1.6B in world-wide sales. Richter has a $189 price target on shares based on a blend of discounted cash flow for $161 per shares and M&A value of $349 per share.
09/26/16
CANT
09/26/16
NO CHANGE
Target $182
CANT
Buy
GW Pharmaceuticals price target raised to $182 from $165 at Cantor
09/26/16
PIPR
09/26/16
NO CHANGE
Target $147
PIPR
Overweight
GW 'increasingly well positioned' for FDA submission, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that with three out of three pivotal trials now positive, GW Pharmaceuticals is "increasingly well positioned" for FDA submission next year. Epidiolex continues to demonstrate a "robust and consistent effect in a drug refractory population," Schimmer tells investors in a research note after GW announced top-line data from the second Phase 3 study in Lennox-Gastaut Syndrome. He reiterates an Overweight rating on the shares with a $147 price target.
10/04/16
LEER
10/04/16
INITIATION
Target $162
LEER
Outperform
GW Pharmaceuticals reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of GW Pharmaceuticals with an Outperform rating and $162 price target.
ONCE Spark Therapeutics
$60.49

-2.48 (-3.94%)

09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/02/16
STFL
09/02/16
INITIATION
STFL
Buy
Spark Therapeutics initiated with a Buy at Stifel
Target $73.
07/12/16
RBCM
07/12/16
INITIATION
Target $70
RBCM
Outperform
Spark Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Michael Yee initiated Spark Therapeutics with an Outperform and a correct price target of $70. Yee believes Spark is the "pure-play" leader in gene therapy and is one of the best investment ways to play this technology with multiple drugs in the clinic now and through 2017.
RDUS Radius Health
$52.08

-0.93 (-1.75%)

08/15/16
JEFF
08/15/16
NO CHANGE
Target $46
JEFF
Hold
Radius Health price target raised to $46 from $37 at Jefferies
Jefferies analyst Eun Yang raised her price target for Radius Health to $46 but keeps a Hold rating on the shares. The analyst says her firm's physician poll shows convenient abalo-TD patch for osteoporosis, if successful, would increase abalo use by 25%-30%. Yang adds that while she isn't taking a "strong view" on recent M&A speculation, some of rumored buyers for Radius "don't seem a right fit."
08/04/16
08/04/16
DOWNGRADE

Sell
Followup: Radius Health downgraded to Sell from Hold at Maxim
As previously reported, Maxim downgraded Radius Health to Sell from Hold with a $24 price target. Analyst Jason McCarthy believes Radius shares are overvalued and continues to believe that Abaloparatide-SC will likely gain approval in 2017 in both the U.S. and Europe, but faces a mature Forteo market, competition from Biosimilar Forteo in 2018, and patients opting for alternative therapies.
08/04/16
MAXM
08/04/16
DOWNGRADE
MAXM
Sell
Radius Health downgraded to Sell from Hold at Maxim
09/21/16
HCWC
09/21/16
NO CHANGE
Target $71
HCWC
Buy
Radius Health price target raised to $71 from $55 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Radius Health to $71 saying results of the second generation transdermal patch in postmenopausal women are promising. ABL-TD patch could not only replace the anabolic drugs on the market, it could expand the market "significantly," Werther tells investors in a research note. She keeps a Buy rating on Radius.
SAGE SAGE Therapeutics
$43.54

-2.36 (-5.14%)

10/04/16
LEER
10/04/16
INITIATION
Target $68
LEER
Outperform
SAGE Therapeutics reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of SAGE Therapeutics with an Outperform rating and $68 price target.
09/13/16
RAJA
09/13/16
INITIATION
Target $75
RAJA
Outperform
SAGE Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated SAGE Therapeutics with an Outperform and a $75 price target. Raymond likes the setup on SAGE shares as key validation of its unique central nervous system drug development approach nears through pivotal SAGE-547 data, expected 1H 2017. Combining this with a pipeline holding numerous unmodeled call options and a platform capable of generating novel agents in a space lacking innovation, he believes shares will move higher.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
09/06/16
ADAM
09/06/16
NO CHANGE
Target $110
ADAM
Buy
SAGE Therapeutics breakthrough designation rare for FDA, says Canaccord
Canaccord analyst John Newman said SAGE Therapeutics' breakthrough designation for SAGE-547 is rare for the FDA to give in central nervous system disorders, suggesting the agency was impressed with the clinical data. Newman expects the breakthrough status to shorten the regulatory timing and allow for more flexibility in study design. The analyst rates SAGE a Buy with a $110 price target.
KITE Kite Pharma
$55.66

-0.75 (-1.33%)

09/27/16
STFL
09/27/16
NO CHANGE
STFL
Kite Pharma data much better than standard of care, says Stifel
Stifel analyst Thomas Shrader says that Kite reported a complete response rate of 52% for its KTE-C19 drug in DLBCL, versus the standard of care's complete response rate of about 8%. The analyst says that the results exceed the level needed for FDA approval. He keeps a $74 price target and Buy rating on the shares.
09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Kite Pharma data positive, says RBC Capital
RBC Capital analyst Michael Yee says that Kite reported positive Phase II data for its KTE-C19 drug in DLBCL with a 47% complete response rate which beat expectations. The analyst says that the complete response rate "is very supportive of FDA approval." He keeps an Outperform rating on the shares.
09/27/16
COWN
09/27/16
NO CHANGE
COWN
Outperform
Efficacy of Kite's KTE-C19 'impressive,' safety 'acceptable,' says Cowen
Cowen analyst Eric Schmidt thinks the 33% complete remissions rate at three months in chemorefractory aggressive NHL patients in Kite Pharma's ZUMA-1 trial is "impressive" and that the safety experience in the trial is "acceptable." The two deaths reported in the trial need to be considered not only in the context of the treatment's efficacy but also in the context of the disease, said Schmidt, who continues to model KTE-C19 as a greater than $1B product and keeps an Outperform rating on Kite Pharma shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.

TODAY'S FREE FLY STORIES

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

AEP

American Electric

$67.83

-0.27 (-0.40%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Hot Stocks
AEP Generation Resources seeks bids for supply of coal »

AEP Generation Resources,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

, FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Hot Stocks
Whitney to acquire branches, assets, liabilities of First NBC from FDIC »

Hancock Holding Company…

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TSLA

Tesla

$314.07

5.44 (1.76%)

17:31
04/28/17
04/28
17:31
04/28/17
17:31
Periodicals
Tesla aims to hire engineers from Mexico to work at CA plant, Reuters says »

Tesla is aiming to hire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:22
04/28/17
04/28
17:22
04/28/17
17:22
Hot Stocks
Lockheed Martin awarded $332.1M government contract »

Lockheed Martin, Orlando,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$184.83

1.61 (0.88%)

17:21
04/28/17
04/28
17:21
04/28/17
17:21
Hot Stocks
Boeing awarded $541M government contract modification »

The Boeing Co., Ridley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

, RAD

Rite Aid

$4.00

0.05 (1.27%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Periodicals
Walgreens to push regulators over decision on Rite Aid deal, NY Post says »

Walgreens (WBA) will…

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

RAD

Rite Aid

$4.00

0.05 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$28.99

-0.09 (-0.31%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Hot Stocks
General Electric awarded $670.7M government contract »

General Electric, Lynn,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

  • 22

    Jun

SIX

Six Flags

$62.61

-0.26 (-0.41%)

17:19
04/28/17
04/28
17:19
04/28/17
17:19
Hot Stocks
Six Flags in agreement to repurchase 5M shares from HP Partners »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 17

    May

  • 18

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:18
04/28/17
04/28
17:18
04/28/17
17:18
Hot Stocks
Lockheed Martin awarded $1.38B government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SBBP

Strongbridge Biopharma

$4.50

0.05 (1.12%)

17:16
04/28/17
04/28
17:16
04/28/17
17:16
Syndicate
Breaking Syndicate news story on Strongbridge Biopharma »

Strongbridge Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

CYH

Community Health

$8.61

0.18 (2.14%)

17:12
04/28/17
04/28
17:12
04/28/17
17:12
Hot Stocks
Community Health completes divestiture of Anniston, Alabama hospital »

Community Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

MRUS

Merus

$22.20

-0.14 (-0.63%)

17:07
04/28/17
04/28
17:07
04/28/17
17:07
Earnings
Merus reports Q4 EPS (EUR1.91) vs. (EUR0.77) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

AEZS

Aeterna Zentaris

$3.35

0.3 (9.84%)

17:01
04/28/17
04/28
17:01
04/28/17
17:01
Hot Stocks
Aeterna Zentaris to announces top-line Zoptrex phase 3 results on Monday »

Aeterna Zentaris will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

ANY

Sphere 3D

$0.19

-0.006 (-3.13%)

17:00
04/28/17
04/28
17:00
04/28/17
17:00
Syndicate
Breaking Syndicate news story on Sphere 3D »

Sphere 3D files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

MRUS

Merus

$22.20

-0.14 (-0.63%)

16:56
04/28/17
04/28
16:56
04/28/17
16:56
Hot Stocks
Merus provides anticipated 2017 pipeline milestones »

Merus provided 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.